Interferon-α abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis

Journal of Rheumatology

Volumn 40, Issue 10, 2013, Pages 1683-1696

  Abeler Dörner, Lucie ^d,f   Rieger, Cosima C ^d   Berger, Bartlomiej ^d   Weyd, Heiko ^d   Gräf, Daniela ^d   Pfrang, Sandra ^d   Tarner, Ingo H ^a   Schwarting, Andreas ^b   Lorenz, Hanns Martin ^c   Müller Ladner, Ulf ^a   Krammer, Peter H ^d   Kuhn, Annegret ^d,e  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Annexin al; Apoptosis; Autoimmune diseases; Dendritic cells; Interferon ; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; LA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; STEROID; TUMOR NECROSIS FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL INTERACTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IN VITRO STUDY; LOW DRUG DOSE; MALE; MONOCYTE; NEUTROPHIL; PHAGOCYTE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANNEXIN A1; APOPTOSIS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; INTERFERON-Α; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; APOPTOSIS; AUTOANTIBODIES; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-17; INTERLEUKIN-1BETA; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; U937 CELLS;

EID: 84885153163     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121299     Document Type: Article

References (50)

1. Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;11:1271-7.
2. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
3. Castro J, Balada E, Ordi-Ros J, Vilardell-Tarrés M. The complex immunogenetic basis of systemic lupus erythematosus. Autoimmun Rev 2008;7:345-51.
4. Morel L. Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol 2010;6:348-57.
5. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010;16:47-57.
6. Cordeiro A, Isenberg D. Novel therapies in lupus - focus on nephritis. Acta Reumatol Port 2008;33:157-69.
7. King J, Hahn B. Systemic lupus erythematosus: modern strategies for management - a moving target. Clin Rheumatol 2007;21:971-87.
8. Pego-Reigosa JM, Isenberg DA. Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opin Investig Drugs 2007;17:31-41.
9. Fairhurst A, Wandstrat AE, Wakeland EK, Frederick WA. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. In: Alt FW. Advances in immunology. New York: Academic Press; 2006:1-69.
10. Wong C, Ho C, Li E, Lam C. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589-93.
11. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.
12. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30.
13. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
14. Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006;54:939-50.
15. Herrmann M, Voll RE, Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000;21:424-6.
16. Muñoz L, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008;17:371-5.
17. Cohen P, Caricchio R. Genetic models for the clearance of apoptotic cells. Rheum Dis Clin North Am 2004;3:473-86, viii.
18. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.
19. Huang F-P, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000;191:435-44.
20. Steinman R, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003;987:15-25.
21. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011;1238:91-8.
22. Bencivelli W, Vitali C, Isenberg D, Smolen J, Snaith M, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
23. Romani N, Gruner S, Brang D, Kämpgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
24. Weyd H, Abeler-Dorner L, Linke B, Mahr A, Jahndel V, Pfrang S, et al. Annexin A1 on the surface of early apoptotic cells suppresses CD8 (+) T cell immunity. PLoS One 2013;8:e62449.
25. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
26. Monrad S, Kaplan M. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol Res 2007;37:135-45.
27. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394-9.
28. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-9.
29. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of [gamma]-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007;14:1848-50.
30. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
31. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 2002;51:351-7.
32. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17:565-77.
33. Minta J, Pambrun L. In vitro induction of cytologic and functional differentiation of the immature human monocytelike cell line U-937 with phorbol myristate acetate. Am J Pathol 1985;1:111-26.
34. Decker P, Singh-Jasuja H, Haager S, Kötter I, Rammensee HG. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol 2005;174:3326-34.
35. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17.
36. Migliorini P, Anzilotti C, Pratesi F, Quattroni P, Bargagna M, Dinarello CA, et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw 2010;21:264-71.
37. Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011;11:75-80.
38. Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy RJ, Bell AL. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis 1999;58:309-14.
39. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
40. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010;6:280-9.
41. Kretz CC, Norpo M, Abeler-Dorner L, Linke B, Haust M, Edler L, et al. Anti-annexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus. Exp Dermatol 2010;19:919-21.
42. Köller M, Zwölfer B, Steiner G, Smolen JS, Scheinecker C. Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol 2004;16:1595-604.
43. Ding D, Mehta H, McCune W, Kaplan M. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol 2006;177:5878-89.
44. Berkun Y, Verbovetski I, Ben-Ami A, Paran D, Caspi D, Krispin A, et al. Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus. Euro J Immunol 2008;38:2896-904.
45. Muñoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009;60:1733-42.
46. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18:676-82.
47. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385-93.
48. Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008;181:8761-6.
49. Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010;37:81-5.
50. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10:778-85.